Vincerx Pharma (VINC) said its VIP943 leukemia drug showed "promising safety and tolerability," achieving two complete responses to date in a phase 1 dose-escalation study
The VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.
Another data update is expected by the end of the year, the company said.
In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to "champion its future development" in order to focus on VIP943.
Vincerx expects a cash runway into early 2025.
Shares of the company jumped 15% in after-hours activity.
Price: 0.8000, Change: +0.10, Percent Change: +14.61
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。